Organizations are releasing patient education materials about what biosimilars are, what questions patients should ask, and other things they might want to know. The latest such example comes from Susan G. Komen, which recently released a guide to using biosimilars and biologics for breast cancer.
2019 saw the launch of long-awaited biosimilars for trastuzumab (referencing Herceptin) for the treatment of HER2-positive breast cancer.
With uptake in the United States lagging behind the use of biosimilars elsewhere around the world, patient education is considered key. To that end, organizations are releasing patient education materials about what biosimilars are, what questions patients should ask, and other things they might want to know.
The latest such example comes from Susan G. Komen, which recently released a guide to using biologics and biosimilars for breast cancer, including trastuzumab (referencing Herceptin) and pertuzumab (sold as Perjeta).
Trastuzumab is given in some regimens together with pertuzumab to improve clinical benefit; the 2 antibodies bind to HER2 at different subdomains and have a synergistic effect.
Biosimilar trastuzumab has also made combination trastuzumab/pertuzumab treatment more affordable, allowing greater patient access. Biosimilars to pertuzumab are in development, but are not yet launched.
The educational materials include a fact sheet, a handout of questions to ask one’s physician, and a related video.
The materials stress that, “It’s not possible to make an exact copy of the biologic because it’s a living thing. However, a biosimilar is highly similar to the original biologic drug and works the same way in the body.”
It also stresses the role of the FDA in approving biosimilars, noting that they must have the same safety, the same effectiveness, and similar side effects, and must be given in the same form.
The website also notes that biosimilar costs may fall over time but for now, the organization says it’s unknown how costs will affect patients.
Among the questions to ask a clinician, the organization suggests asking what the provider's experience is with biosimilars, how a patient would know if they’re getting a biosimilar, how biosimilars are tested for safety and effectiveness, who makes the decision about whether to use a reference product or a biosimilar, and whether these products will have any effect on treatment or outcomes.
Besides listing biosimilars to trastuzumab, the website also includes information about biosimilars that boost white blood cell counts in patients undergoing chemotherapy (filgrastim and pegfilgrastim).
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim
November 25th 2023A phase 1 analysis confirms that romiplostim biosimilar candidate GP40141 has comparable pharmacokinetic (PK) and pharmacodynamic (PD) parameters in healthy volunteers compared with the reference product.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).